{"count": 21, "results": [{"_id": "32647571", "pmid": 32647571, "pmcid": "PMC7336499", "title": "Metformin sensitizes therapeutic agents and improves outcome in pre-clinical and clinical diffuse large B-cell lymphoma", "journal": "Cancer Metab", "authors": ["Singh AR", "Gu JJ", "Zhang Q", "Torka P", "Sundaram S", "Mavis C", "Hernandez-Ilizaliturri FJ"], "date": "2020-07-06T00:00:00Z", "doi": "10.1186/s40170-020-00213-w", "meta_date_publication": "2020", "meta_volume": "8", "meta_issue": "", "meta_pages": "10", "score": 50277.63, "text_hl": "To further investigate the effect of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ on the cell cycle in @<m>DISEASE_Lymphoma</m> @DISEASE_MESH:D008223 @@@lymphoma@@@ cells, we performed flow cytometric analysis of cells in response to the treatment with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ for 48 h. ", "citations": {"NLM": "Singh AR, Gu JJ, Zhang Q, Torka P, Sundaram S, Mavis C, Hernandez-Ilizaliturri FJ. Metformin sensitizes therapeutic agents and improves outcome in pre-clinical and clinical diffuse large B-cell lymphoma Cancer Metab. 2020;8():10. PMID: 32647571", "BibTeX": "@article{32647571, title={Metformin sensitizes therapeutic agents and improves outcome in pre-clinical and clinical diffuse large B-cell lymphoma}, author={Singh AR and Gu JJ and Zhang Q and Torka P and Sundaram S and Mavis C and Hernandez-Ilizaliturri FJ}, journal={Cancer Metab}, volume={8}, pages={10}}"}}, {"_id": "34557403", "pmid": 34557403, "pmcid": "PMC8454268", "title": "Metabolic Switch and Cytotoxic Effect of Metformin on Burkitt Lymphoma", "journal": "Front Oncol", "authors": ["Bagaloni I", "Visani A", "Biagiotti S", "Ruzzo A", "Navari M", "Etebari M", "Mundo L", "Granai M", "Lazzi S", "Isidori A", "Loscocco F", "Li J", "Leoncini L", "Visani G", "Magnani M", "Piccaluga PP"], "date": "2021-09-02T00:00:00Z", "doi": "10.3389/fonc.2021.661102", "meta_date_publication": "2021", "meta_volume": "11", "meta_issue": "", "meta_pages": "661102", "score": 50257.734, "text_hl": "In this study, we aimed to assess @CHEMICAL_Glucose @CHEMICAL_MESH:D005947 @@@glucose@@@ metabolism activation in @SPECIES_9606 @@@human@@@ @<m>DISEASE_Lymphoma</m> @DISEASE_MESH:D008223 @@@lymphomas@@@ and evaluate how @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ can exert its action on @<m>DISEASE_Lymphoma</m> @DISEASE_MESH:D008223 @@@lymphoma@@@ cells. ", "citations": {"NLM": "Bagaloni I, Visani A, Biagiotti S, Ruzzo A, Navari M, Etebari M, Mundo L, Granai M, Lazzi S, Isidori A, Loscocco F, Li J, Leoncini L, Visani G, Magnani M, Piccaluga PP. Metabolic Switch and Cytotoxic Effect of Metformin on Burkitt Lymphoma Front Oncol. 2021;11():661102. PMID: 34557403", "BibTeX": "@article{34557403, title={Metabolic Switch and Cytotoxic Effect of Metformin on Burkitt Lymphoma}, author={Bagaloni I and Visani A and Biagiotti S and Ruzzo A and Navari M and Etebari M and Mundo L and Granai M and Lazzi S and Isidori A and Loscocco F and Li J and Leoncini L and Visani G and Magnani M and Piccaluga PP}, journal={Front Oncol}, volume={11}, pages={661102}}"}}, {"_id": "33747367", "pmid": 33747367, "pmcid": "PMC7967492", "title": "Metformin - its anti-cancer effects in hematologic malignancies", "journal": "Oncol Rev", "authors": ["Podhorecka M"], "date": "2021-02-26T00:00:00Z", "doi": "10.4081/oncol.2021.514", "meta_date_publication": "2021 Feb 26", "meta_volume": "15", "meta_issue": "1", "meta_pages": "514", "score": 50256.703, "text_hl": "Interestingly, it was also reported that @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ is able to reduce the risk of @<m>DISEASE_Lymphoma</m> @DISEASE_MESH:D008223 @@@lymphoma@@@ incidence. ", "citations": {"NLM": "Podhorecka M. Metformin - its anti-cancer effects in hematologic malignancies Oncol Rev. 2021 Feb 26;15(1):514. PMID: 33747367", "BibTeX": "@article{33747367, title={Metformin - its anti-cancer effects in hematologic malignancies}, author={Podhorecka M}, journal={Oncol Rev}, volume={15}, number={1}, pages={514}}"}}, {"_id": "34195068", "pmid": 34195068, "pmcid": "PMC8236717", "title": "Alteration of Cholesterol Metabolism by Metformin Is Associated With Improved Outcome in Type II Diabetic Patients With Diffuse Large B-Cell Lymphoma", "journal": "Front Oncol", "authors": ["Jiang XN", "Zhang Y", "Wang WG", "Sheng D", "Zhou XY", "Li XQ"], "date": "2021-06-14T00:00:00Z", "doi": "10.3389/fonc.2021.608238", "meta_date_publication": "2021", "meta_volume": "11", "meta_issue": "", "meta_pages": "608238", "score": 50254.184, "text_hl": "Recent studies have demonstrated the benefits of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ on @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Lymphoma</m> @DISEASE_MESH:D008223 @@@lymphomas@@@. ", "citations": {"NLM": "Jiang XN, Zhang Y, Wang WG, Sheng D, Zhou XY, Li XQ. Alteration of Cholesterol Metabolism by Metformin Is Associated With Improved Outcome in Type II Diabetic Patients With Diffuse Large B-Cell Lymphoma Front Oncol. 2021;11():608238. PMID: 34195068", "BibTeX": "@article{34195068, title={Alteration of Cholesterol Metabolism by Metformin Is Associated With Improved Outcome in Type II Diabetic Patients With Diffuse Large B-Cell Lymphoma}, author={Jiang XN and Zhang Y and Wang WG and Sheng D and Zhou XY and Li XQ}, journal={Front Oncol}, volume={11}, pages={608238}}"}}, {"_id": "37364455", "pmid": 37364455, "title": "Repurposing Metformin in hematologic tumor: State of art.", "journal": "Curr Probl Cancer", "authors": ["Hu M", "Chen Y", "Ma T", "Jing L"], "date": "2023-06-20T00:00:00Z", "doi": "10.1016/j.currproblcancer.2023.100972", "meta_date_publication": "2023 Jun 20", "meta_volume": "47", "meta_issue": "4", "meta_pages": "100972", "score": 50249.95, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ also plays an important role in the treatment of @DISEASE_Hematologic_Neoplasms @DISEASE_MESH:D019337 @@@hematologic tumors@@@, especially in @DISEASE_Leukemia @DISEASE_MESH:D007938 @@@leukemia@@@, @<m>DISEASE_Lymphoma</m> @DISEASE_MESH:D008223 @@@lymphoma@@@, and @DISEASE_Multiple_Myeloma @DISEASE_MESH:D009101 @@@multiple myeloma@@@ (@DISEASE_Multiple_Myeloma @DISEASE_MESH:D009101 @@@MM@@@). ", "citations": {"NLM": "Hu M, Chen Y, Ma T, Jing L. Repurposing Metformin in hematologic tumor: State of art. Curr Probl Cancer. 2023 Jun 20;47(4):100972. PMID: 37364455", "BibTeX": "@article{37364455, title={Repurposing Metformin in hematologic tumor: State of art.}, author={Hu M and Chen Y and Ma T and Jing L}, journal={Curr Probl Cancer}, volume={47}, number={4}, pages={100972}}"}}, {"_id": "36077749", "pmid": 36077749, "pmcid": "PMC9454423", "title": "Activation of the Anaphase Promoting Complex Reverses Multiple Drug Resistant Cancer in a Canine Model of Multiple Drug Resistant Lymphoma", "journal": "Cancers (Basel)", "authors": ["Arnason TG", "MacDonald-Dickinson V", "Gaunt MC", "Davies GF", "Lobanova L", "Trost B", "Gillespie ZE", "Waldner M", "Baldwin P", "Borrowman D", "Marwood H", "Vizeacoumar FS", "Vizeacoumar FJ", "Eskiw CH", "Kusalik A", "Harkness TAA"], "date": "2022-08-30T00:00:00Z", "doi": "10.3390/cancers14174215", "meta_date_publication": "2022 Aug 30", "meta_volume": "14", "meta_issue": "17", "meta_pages": "", "score": 50249.402, "text_hl": "Future studies will focus on naive @SPECIES_9615 @@@dogs@@@ as they enter the clinic for a blinded study with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ to determine whether early introduction of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ can delay the onset of drug resistant @<m>DISEASE_Lymphoma</m> @DISEASE_MESH:D008223 @@@lymphoma@@@.", "citations": {"NLM": "Arnason TG, MacDonald-Dickinson V, Gaunt MC, Davies GF, Lobanova L, Trost B, Gillespie ZE, Waldner M, Baldwin P, Borrowman D, Marwood H, Vizeacoumar FS, Vizeacoumar FJ, Eskiw CH, Kusalik A, Harkness TAA. Activation of the Anaphase Promoting Complex Reverses Multiple Drug Resistant Cancer in a Canine Model of Multiple Drug Resistant Lymphoma Cancers (Basel). 2022 Aug 30;14(17):. PMID: 36077749", "BibTeX": "@article{36077749, title={Activation of the Anaphase Promoting Complex Reverses Multiple Drug Resistant Cancer in a Canine Model of Multiple Drug Resistant Lymphoma}, author={Arnason TG and MacDonald-Dickinson V and Gaunt MC and Davies GF and Lobanova L and Trost B and Gillespie ZE and Waldner M and Baldwin P and Borrowman D and Marwood H and Vizeacoumar FS and Vizeacoumar FJ and Eskiw CH and Kusalik A and Harkness TAA}, journal={Cancers (Basel)}, volume={14}, number={17}}"}}, {"_id": "34745769", "pmid": 34745769, "pmcid": "PMC8565822", "title": "Metformin promotes anticancer activity of NK cells in a p38 MAPK dependent manner", "journal": "Oncoimmunology", "authors": ["Xia W", "Qi X", "Li M", "Wu Y", "Sun L", "Fan X", "Yuan Y", "Li J"], "date": "2021-10-29T00:00:00Z", "doi": "10.1080/2162402X.2021.1995999", "meta_date_publication": "2021", "meta_volume": "10", "meta_issue": "1", "meta_pages": "1995999", "score": 50249.06, "text_hl": "...@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ improves NK cell-mediated @<m>DISEASE_Lymphoma</m> @DISEASE_MESH:D008223 @@@lymphoma@@@ clearance in vivo.", "citations": {"NLM": "Xia W, Qi X, Li M, Wu Y, Sun L, Fan X, Yuan Y, Li J. Metformin promotes anticancer activity of NK cells in a p38 MAPK dependent manner Oncoimmunology. 2021;10(1):1995999. PMID: 34745769", "BibTeX": "@article{34745769, title={Metformin promotes anticancer activity of NK cells in a p38 MAPK dependent manner}, author={Xia W and Qi X and Li M and Wu Y and Sun L and Fan X and Yuan Y and Li J}, journal={Oncoimmunology}, volume={10}, number={1}, pages={1995999}}"}}, {"_id": "32304100", "pmid": 32304100, "title": "Statin and cyclooxygenase-2 inhibitors improve survival in newly diagnosed diffuse large B-cell lymphoma: a large population-based study of 4913 subjects.", "journal": "Br J Haematol", "authors": ["Smyth L", "Blunt DN", "Gatov E", "Nagamuthu C", "Croxford R", "Mozessohn L", "Cheung MC"], "date": "2020-11-01T00:00:00Z", "doi": "10.1111/bjh.16635", "meta_date_publication": "2020 Nov", "meta_volume": "191", "meta_issue": "3", "meta_pages": "396-404", "score": 50243.168, "text_hl": "Preclinical data suggests anti-@<m>DISEASE_Lymphoma</m> @DISEASE_MESH:D008223 @@@lymphoma@@@ potential for statins, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ and cyclooxygenase-2 (COX-2) inhibitors. ", "citations": {"NLM": "Smyth L, Blunt DN, Gatov E, Nagamuthu C, Croxford R, Mozessohn L, Cheung MC. Statin and cyclooxygenase-2 inhibitors improve survival in newly diagnosed diffuse large B-cell lymphoma: a large population-based study of 4913 subjects. Br J Haematol. 2020 Nov;191(3):396-404. PMID: 32304100", "BibTeX": "@article{32304100, title={Statin and cyclooxygenase-2 inhibitors improve survival in newly diagnosed diffuse large B-cell lymphoma: a large population-based study of 4913 subjects.}, author={Smyth L and Blunt DN and Gatov E and Nagamuthu C and Croxford R and Mozessohn L and Cheung MC}, journal={Br J Haematol}, volume={191}, number={3}, pages={396-404}}"}}, {"_id": "36276140", "pmid": 36276140, "pmcid": "PMC9583025", "title": "Enhanced lipid metabolism confers the immunosuppressive tumor microenvironment in CD5-positive non-MYC/BCL2 double expressor lymphoma", "journal": "Front Oncol", "authors": ["Liu MK", "Cheng LL", "Yi HM", "He Y", "Li X", "Fu D", "Dai YT", "Fang H", "Cheng S", "Xu PP", "Qian Y", "Feng Y", "Liu Q", "Wang L", "Zhao WL"], "date": "2022-10-06T00:00:00Z", "doi": "10.3389/fonc.2022.885011", "meta_date_publication": "2022", "meta_volume": "12", "meta_issue": "", "meta_pages": "885011", "score": 50242.734, "text_hl": "In vitro, a @DISEASE_Lymphoma_Large_B_Cell_Diffuse @DISEASE_MESH:D016403 @@@DLBCL@@@ cell line (LY10) overexpressing @GENE_CD5 @GENE_921 @@@CD5@@@ significantly increased M2 proportion in comparison with control when cocultured with peripheral blood mononuclear cells (PBMCs). The addition of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ significantly decreased the M2 proportion and the CD36 expression level in the coculture systems, indicating that @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ could target altered @CHEMICAL_Lipids @CHEMICAL_MESH:D008055 @@@lipid@@@ metabolism and decrease M2 macrophages in @DISEASE_Lymphoma_Large_B_Cell_Diffuse @DISEASE_MESH:D016403 @@@DLBCL@@@, especially in @GENE_CD5 @GENE_921 @@@CD5@@@+ non-DE @<m>DISEASE_Lymphoma</m> @DISEASE_MESH:D008223 @@@lymphoma@@@. ", "citations": {"NLM": "Liu MK, Cheng LL, Yi HM, He Y, Li X, Fu D, Dai YT, Fang H, Cheng S, Xu PP, Qian Y, Feng Y, Liu Q, Wang L, Zhao WL. Enhanced lipid metabolism confers the immunosuppressive tumor microenvironment in CD5-positive non-MYC/BCL2 double expressor lymphoma Front Oncol. 2022;12():885011. PMID: 36276140", "BibTeX": "@article{36276140, title={Enhanced lipid metabolism confers the immunosuppressive tumor microenvironment in CD5-positive non-MYC/BCL2 double expressor lymphoma}, author={Liu MK and Cheng LL and Yi HM and He Y and Li X and Fu D and Dai YT and Fang H and Cheng S and Xu PP and Qian Y and Feng Y and Liu Q and Wang L and Zhao WL}, journal={Front Oncol}, volume={12}, pages={885011}}"}}, {"_id": "35344184", "pmid": 35344184, "title": "Reduced Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma in Type 2 Diabetes Mellitus: Will Metformin Never Stop Its Pleasant Surprises?", "journal": "Adv Ther", "authors": ["Papachristou S", "Popovic DS", "Papanas N"], "date": "2022-06-01T00:00:00Z", "doi": "10.1007/s12325-022-02125-1", "meta_date_publication": "2022 Jun", "meta_volume": "39", "meta_issue": "6", "meta_pages": "2283-2286", "score": 50241.44, "text_hl": "@DISEASE_Monoclonal_Gammopathy_of_Undetermined_Significance @DISEASE_MESH:D008998 @@@MGUS@@@ may progress to @DISEASE_Myeloproliferative_Disorders @DISEASE_MESH:D009196 @@@myeloproliferative disorders@@@ or @DISEASE_Multiple_Myeloma @DISEASE_MESH:D009101 @@@multiple myeloma@@@, but very little is known about any modifiable risk factors or any preventative treatment that might delay this progression. @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ has begun to be discussed as a potentially useful agent on the basis of the results of epidemiological and preclinical research showing that it may be beneficial in @SPECIES_9606 @@@patients@@@ with @DISEASE_Leukemia_T_Cell @DISEASE_MESH:D015458 @@@leukaemia@@@, @<m>DISEASE_Lymphoma</m> @DISEASE_MESH:D008223 @@@lymphomas@@@ and @DISEASE_Multiple_Myeloma @DISEASE_MESH:D009101 @@@multiple myeloma@@@. ", "citations": {"NLM": "Papachristou S, Popovic DS, Papanas N. Reduced Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma in Type 2 Diabetes Mellitus: Will Metformin Never Stop Its Pleasant Surprises? Adv Ther. 2022 Jun;39(6):2283-2286. PMID: 35344184", "BibTeX": "@article{35344184, title={Reduced Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma in Type 2 Diabetes Mellitus: Will Metformin Never Stop Its Pleasant Surprises?}, author={Papachristou S and Popovic DS and Papanas N}, journal={Adv Ther}, volume={39}, number={6}, pages={2283-2286}}"}}]}